SAN
FRANCISCO, May 30, 2024 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) management is scheduled to present at
upcoming investor conferences:
- Jefferies Healthcare Conference in New York City on Thursday, June 6, 2024 at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time
- Goldman Sachs 45th Annual Global Healthcare Conference in
Miami on Monday, June 10, 2024 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time
The presentations will be accessible via webcast through links
posted on the Investor Events section of the Nektar website:
https://ir.nektar.com/events-and-presentations/events. The webcasts
will be available for replay until July 6,
2024 and July 10, 2024,
respectively.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology
company focused on developing treatments that address the
underlying immunological dysfunction in autoimmune and chronic
inflammatory diseases. Nektar's lead product candidate,
rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class
regulatory T cell stimulator being evaluated in two Phase
2b clinical trials, one in atopic
dermatitis and one in alopecia areata. Our pipeline also includes a
preclinical candidate NKTR-0165, which is a bivalent tumor necrosis
factor receptor type II agonist antibody. Nektar, together with
various partners, is also evaluating NKTR-255, an investigational
IL-15 receptor agonist designed to boost the immune system's
natural ability to fight cancer, in several ongoing clinical
trials. Nektar is headquartered in San Francisco, California. For further information,
visit www.nektar.com and follow us on LinkedIn.
Contact:
For Investors:
Vivian
Wu of Nektar Therapeutics
628-895-0661
For Media:
David Rosen
of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nektar-management-to-present-at-upcoming-investor-conferences-302160077.html
SOURCE Nektar Therapeutics